AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer-Reference-Cited by-同舟云学术

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

Published:2014-09-11 Issue:11 Volume:371 Page:1028-1038
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Antonarakis Emmanuel S.,Lu Changxue,Wang Hao,Luber Brandon,Nakazawa Mary,Roeser Jeffrey C.,Chen Yan,Mohammad Tabrez A.,Chen Yidong,Fedor Helen L.,Lotan Tamara L.,Zheng Qizhi,De Marzo Angelo M.,Isaacs John T.,Isaacs William B.,Nadal Rosa,Paller Channing J.,Denmeade Samuel R.,Carducci Michael A.,Eisenberger Mario A.,Luo Jun

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1315815

Cited by 2264 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors;Critical Reviews in Oncology/Hematology;2024-11

2. Regulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells after treatment with dutasteride and lovastatin;Neoplasia;2024-11

3. Un-methylation of NUDT21 represses docosahexaenoic acid biosynthesis contributing to enzalutamide resistance in prostate cancer;Drug Resistance Updates;2024-11

4. Docosahexaenoic acid enhances the treatment efficacy for castration-resistant prostate cancer by inhibiting autophagy through Atg4B inhibition;Archives of Biochemistry and Biophysics;2024-10

5. Inhibitors of the transactivation domain of androgen receptor as a therapy for prostate cancer;Steroids;2024-10